166 related articles for article (PubMed ID: 31900164)
1. Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases.
Angata T
J Biomed Sci; 2020 Jan; 27(1):10. PubMed ID: 31900164
[TBL] [Abstract][Full Text] [Related]
2. Siglec-15 as multifunctional molecule involved in osteoclast differentiation, cancer immunity and microbial infection.
Huang R; Zheng J; Shao Y; Zhu L; Yang T
Prog Biophys Mol Biol; 2023 Jan; 177():34-41. PubMed ID: 36265694
[TBL] [Abstract][Full Text] [Related]
3. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis.
Kameda Y; Takahata M; Mikuni S; Shimizu T; Hamano H; Angata T; Hatakeyama S; Kinjo M; Iwasaki N
Bone; 2015 Feb; 71():217-26. PubMed ID: 25460183
[TBL] [Abstract][Full Text] [Related]
4. Molecular structure, expression, and the emerging role of Siglec-15 in skeletal biology and cancer.
Rashid S; Song D; Yuan J; Mullin BH; Xu J
J Cell Physiol; 2022 Mar; 237(3):1711-1719. PubMed ID: 34893976
[TBL] [Abstract][Full Text] [Related]
5. Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice.
Hiruma Y; Tsuda E; Maeda N; Okada A; Kabasawa N; Miyamoto M; Hattori H; Fukuda C
Bone; 2013 Mar; 53(1):87-93. PubMed ID: 23238125
[TBL] [Abstract][Full Text] [Related]
6. Siglec-15 on Osteoclasts Is Crucial for Bone Erosion in Serum-Transfer Arthritis.
Korn MA; Schmitt H; Angermüller S; Chambers D; Seeling M; Lux UT; Brey S; Royzman D; Brückner C; Popp V; Percivalle E; Bäuerle T; Zinser E; Winkler TH; Steinkasserer A; Nimmerjahn F; Nitschke L
J Immunol; 2020 Nov; 205(10):2595-2605. PubMed ID: 33020147
[TBL] [Abstract][Full Text] [Related]
7. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
8. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation.
Hiruma Y; Hirai T; Tsuda E
Biochem Biophys Res Commun; 2011 Jun; 409(3):424-9. PubMed ID: 21586272
[TBL] [Abstract][Full Text] [Related]
9. Siglec-15 recognition of sialoglycans on tumor cell lines can occur independently of sialyl Tn antigen expression.
Murugesan G; Correia VG; Palma AS; Chai W; Li C; Feizi T; Martin E; Laux B; Franz A; Fuchs K; Weigle B; Crocker PR
Glycobiology; 2021 Jan; 31(1):44-54. PubMed ID: 32501471
[TBL] [Abstract][Full Text] [Related]
10. Siglec-15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44.
Liu W; Ji Z; Wu B; Huang S; Chen Q; Chen X; Wei Y; Jiang J
FEBS Lett; 2021 Sep; 595(17):2290-2302. PubMed ID: 34328657
[TBL] [Abstract][Full Text] [Related]
11. Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) mediates periarticular bone loss, but not joint destruction, in murine antigen-induced arthritis.
Shimizu T; Takahata M; Kameda Y; Endo T; Hamano H; Hiratsuka S; Ota M; Iwasaki N
Bone; 2015 Oct; 79():65-70. PubMed ID: 26027508
[TBL] [Abstract][Full Text] [Related]
12. The diverse functions of Siglec-15 in bone remodeling and antitumor responses.
Kang FB; Chen W; Wang L; Zhang YZ
Pharmacol Res; 2020 May; 155():104728. PubMed ID: 32112821
[TBL] [Abstract][Full Text] [Related]
13. Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis.
Li B; Zhang B; Wang X; Zeng Z; Huang Z; Zhang L; Wei F; Ren X; Yang L
Oncoimmunology; 2020 Aug; 9(1):1807291. PubMed ID: 32939323
[TBL] [Abstract][Full Text] [Related]
14. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution.
Angata T; Tabuchi Y; Nakamura K; Nakamura M
Glycobiology; 2007 Aug; 17(8):838-46. PubMed ID: 17483134
[TBL] [Abstract][Full Text] [Related]
15. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.
Takamiya R; Ohtsubo K; Takamatsu S; Taniguchi N; Angata T
Glycobiology; 2013 Feb; 23(2):178-87. PubMed ID: 23035012
[TBL] [Abstract][Full Text] [Related]
16. Identification of Siglec Ligands Using a Proximity Labeling Method.
Chang L; Chen YJ; Fan CY; Tang CJ; Chen YH; Low PY; Ventura A; Lin CC; Chen YJ; Angata T
J Proteome Res; 2017 Oct; 16(10):3929-3941. PubMed ID: 28899088
[TBL] [Abstract][Full Text] [Related]
17. Cell-based glycan arrays for probing glycan-glycan binding protein interactions.
Briard JG; Jiang H; Moremen KW; Macauley MS; Wu P
Nat Commun; 2018 Feb; 9(1):880. PubMed ID: 29491407
[TBL] [Abstract][Full Text] [Related]
18. Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters.
Quirino MWL; Pereira MC; Deodato de Souza MF; Pitta IDR; Da Silva Filho AF; Albuquerque MSS; Albuquerque APB; Martins MR; Pitta MGDR; Rêgo MJBM
Eur J Histochem; 2021 Mar; 65(1):. PubMed ID: 33666065
[TBL] [Abstract][Full Text] [Related]
19. LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma.
Liu Y; Li X; Zhang C; Zhang H; Huang Y
Cancer Sci; 2020 Oct; 111(10):3693-3704. PubMed ID: 32780490
[TBL] [Abstract][Full Text] [Related]
20. Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and -9.
Miyazaki K; Sakuma K; Kawamura YI; Izawa M; Ohmori K; Mitsuki M; Yamaji T; Hashimoto Y; Suzuki A; Saito Y; Dohi T; Kannagi R
J Immunol; 2012 May; 188(9):4690-700. PubMed ID: 22467657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
